[quote=desmond][quote=njtosd][quote=desmond][quote=njtosd] For example, Arena appears to have nothing beyond phase 1 except Lorcaserin (I know, they got good news from the FDA recently) -but they seem to be partnering with Ortho on that one – so Ortho will likely get a big share of potential profits.[/quote]

Eeyore said the same thing.[/quote]

Sorry – I wish I saw it differently. Both my husband and I have spent our working years as patent attorneys for biotech companies (very large to very small). It was exciting in the late 80s and 90s, but there doesn’t seem to be much going on anymore.[/quote]

Arena is up 35% in the last 5 days and 405% ytd, it must take quite a bit to get you excited, for me not much…………….[/quote]

Your original post asked whether people expected a dot com style run up in biotech. My opinion is still – no. Will there be compounds that look promising? Absolutely.
Here’s my question to you: what portion of the proceeds from Lorcaserin will Arena keep? It’s supposed to manufacture for Eisai (sorry, the previous collaboration with Ortho was terminated), a Japanese company that will actually do the selling, and will get a portion of the proceeds (roughly 30-35%). And how will proceeds be calculated? If it was a great deal for Arena I think we’d know more about it . . . .